A company with technology for microRNA compounds has raised €18.5 million in a Series B financing round to advance a product for patients with advanced solid tumours. The company, InteRNA Technologies, is based in the Netherlands. Leading the funding round was AurorA Science, a biotech investment group based in Milan, Italy. As part of the funding, Gabriele Campi of AurorA will join the Dutch company’s board of directors.
